In two studies, the annualized relapse rate was cut nearly in half with twice-daily use of the new drug currently known as BG One study also found that BG could reduce the progression of disability, while the other study found no statistically significant difference between the drug and placebo for rates of disability.
Fox added that the drug was well tolerated in the clinical trial, and appears to be quite safe. Results of the studies are published in the Sept.
Both were funded by the drug's manufacturer, Biogen Idec. Multiple sclerosis is an autoimmune disease that psoriasis remission for years the outside of nerve fibers in the central nervous system, which includes the brain, spine and optic nerves, according to the National Multiple Sclerosis Society NMSS.
Symptoms can include fatigue, numbness in the limbs, balance and coordination problems, bladder or bowel dysfunction, vision problems, pain and even paralysis. That means that people have periods where the disease is very active.
At other times, the disease remits. During these periods of remission, there may be complete or partial recovery of function, and the disease doesn't progress during remission.
Both of the current studies focused on people with the relapsing-remitting form of MS. Fox's study included patients taking milligrams mg of BG twice a day, taking mg three times a day, taking glatiramer acetate an injectable MS drug and taking a placebo. BG was originally developed as a drug to treat the autoimmune skin condition psoriasis.
The annual relapse rate was 0. There were no statistically significant differences in the rate of disability progression among the groups, according to the study.
Psoriasis alapján Naftalan olaj Psoriasis alapján Naftalan olaj Main treatment areas. Although psoriasis is a chronic long term condition with no cure, it can be controlled and go into remission go away. Not all people will be affected in the same way and doctors will class the condition as mild, moderate or severe.
The second study included people taking BG twice a day, people taking the drug three times a day and people on pikkelysömör kezelésére a fejbőr vélemények. Rates of disability progression were 16 percent in the twice-daily group, 18 percent in the thrice-daily group and 27 percent in the placebo group, according to the study.
They illustrate that trying new strategies and tackling new parts of the immune system can be effective," explained Timothy Coetzee, chief research officer at the National Multiple Sclerosis Society. This is an advance in the treatment of MS in my view," Coetzee said.
Fox said that BG appears to modify the immune system psoriasis remission for years without suppressing the immune system, a common problem with some other medications available for MS. Fox said that the new drug also appears to protect nervous system cells from damage, though how that occurs isn't yet clear.
The U. Food and Drug Administration is expected to make a decision on whether or not to approve BG by the end of the year, according to Fox. No information on what the cost of BG will be is currently available.
- New Pill Shows Promise Against Relapsing Multiple Sclerosis - Consumer Health News | HealthDay
- Clinical Trials Register
- Szőrtelenítés után vörös foltok az arcon
- Nézze meg a képeket, és olvassa el az egyéb tüneteket, okokat és kezelést.
- Dovobet pikkelysömör prix auto Allergia nikkel psoriasis kezelésére; Apicoltura biológia psoriasisra; amely teszteli át a psoriasis; Jelenség koebner psoriasis a fejbőr; Kutatási orvosok hívja psoriasis egy titokzatos betegség, és mindezt azért, mert; Plantes mystères; Patrick yesudian psoriasis a fejbőrön; Produits du terroir; Adalimumab psoriasis pdf író.